secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001411690-23-000080
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q3 revenue $9.3M (+29% YoY); $80M convertible notes completed; $33M cost savings plan
--------------------------------------------------------------------------------

- Q3 revenue $9.3M, +29% YoY; GAAP gross margin 30% vs 25% YoY; non-GAAP operating expense $31.8M.
- Completed $80M convertible notes offering (Oct 13), extending cash runway; cash & securities $63.6M.
- Cost reduction initiatives expected to save ~$33M annually starting 2024; reiterated FY2023 rev guidance $35-$38M.
- Saphyr installed base 301 (+39% YoY); flowcells sold 6,176 (+55% YoY); OGM publications up 61% YoY.
- Appointed Gülsen Kama as CFO effective Sept 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/0001411690-23-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/bngo-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001411690-23-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer